Browsing Tag
Daniel O’Day
15 posts
FDA grants EUA for Gilead’s investigational COVID-19 drug remdesivir
Remdesivir EUA status : The US has officially pushed the use of remdesivir for treating the novel coronavirus…
May 4, 2020
Gilead Sciences wraps up $4.9bn acquisition of Forty Seven
Gilead Sciences has completed its previously announced $4.9 billion acquisition of Forty Seven, a clinical-stage immuno-oncology company based…
April 13, 2020
Gilead Sciences to acquire immuno-oncology company Forty Seven for $4.9bn
Gilead Sciences acquisition of Forty Seven : US biotech company Gilead Sciences has signed an all-cash deal worth…
March 3, 2020
Gilead Sciences bags Descovy FDA approval for prevention of HIV infection
Descovy FDA approval : Gilead Sciences’ Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) has…
December 1, 2019
Gilead Sciences names Lilly senior VP Christi L. Shaw as Kite CEO
US biopharma company Gilead Sciences has named Christi L. Shaw as the new chief executive officer of its…
July 12, 2019